Skip to main content
SpringerLink
Log in

Pulmonale Toxizitäten von Krebstherapien - Teil 1

Checkpointinhibitor assoziierte Pneumonitiden

  • Supportivtherapie
  • AGSMO-Fortbildung
  • Published:
Im Fokus Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© Klinikum Nürnberg

Abb. 2

© Klinikum Nürnberg

Abb. 3
Abb. 4

Literatur

  1. Wang Y et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5(7):1008-19

  2. Suresh K et al. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. J Thorac Oncol. 2018;13(12):1930-9

  3. Delaunay M et al. Management of pulmonary toxicity associated with immune checkpoint inhibitors. Eur Respir Rev. 2019;28(154):190012

  4. Wang DY et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(12):1721-1728. Erratum in: JAMA Oncol. 2018;4(12):1792

  5. El Osta B et al. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1-12

  6. Khoja L et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic re-view. Ann Oncol. 2017;28(10):2377-85

  7. Su Q et al. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. Front Immunol. 2019;10:108

  8. Gu L et al. The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis. BMC Cancer. 2019;19(1):559

  9. Tone M et al. High mortality and poor treatment efficacy of immune check-point inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. Thorac Cancer. 2019;10(10):2006-12

  10. Li M et al. Brief report: in-haled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. Cancer Immunol Immunother. 2020;69(11):2403-8

  11. Zhang C et al. Checkpoint inhibitor pneumonitis in Chinese lung cancer patients: clinical characteristics and risk factors. Ann Palliat Med. 2020;9(6):3957-65

  12. Shaverdian N et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895-903. Erratum in: Lancet Oncol. 2017;18(7):e371

  13. Hwang WL et al. Clini-cal Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibi-tors and Thoracic Radiotherapy. JAMA Oncol. 2018;4(2):253-5

  14. Lin SH et al. Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer. J Clin Oncol. 2019;37(15 Suppl):8512

  15. Chan KK, Bass AR. Autoimmune complications of immunotherapy: pathophysiology and management. BMJ. 2020;369:m 736

  16. Wang YN et al. Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibi-tor pneumonitis in patients with non-small cell lung cancer. Oncol Lett. 2020;20(1):611-22

  17. Lin X et al. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study. Clin Transl Oncol. 2020; https://doi.org/10.1007/s12094-020-02432-5

  18. Correale P et al. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. Cells. 2020;9(9):1964

  19. Wang H et al. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thorac Cancer. 2020;11(1):191-7

  20. Koelzer VH et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer. 2016;4:13

  21. Berthod G et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin On-col. 2012;30(17):e156-9

  22. Barjaktarevic IZ et al. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest. 2013;143(3):858-861

  23. Larsen BT et al. Clinical and Histopatho-logic Features of Immune Checkpoint Inhibitor-related Pneumonitis. Am J Surg Pathol. 2019;43(10):1331-40

  24. Naidoo J et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017;35(7):709-17. Erratum in: J Clin Oncol. 2017;35(22):2590

  25. Balaji A et al. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. J Immunother Cancer. 2021;9(1):e001731

  26. Nishino M et al. Thoracic Complications of Precision Cancer Thera-pies: A Practical Guide for Radiologists in the New Era of Cancer Care. Radiographics 2017;37(5):1371-87

  27. Bukamur H et al. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab. South Med J. 2020;113(11):600-5

  28. Suresh K et al. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. J Clin Invest. 2019;129(10):4305-15

  29. Strippoli S et al. Cellular analysis of bronchoalveolar lavage fluid to narrow dif-ferential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma. J Transl Med. 2020;18(1):473

  30. Brahmer JR et al. National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-68

  31. Thompson JA et al. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019;17(3):255-89

  32. Shannon VR et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Support Care Cancer. 2020;28(12):6145-57

Download references

Author information

Authors and Affiliations

  1. Univ. Klinik f. Inn. Medizin 3, Paracelsus Med. Privatuniversität, Klinikum Nürnberg, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Schweiz

    Markus Horneber &  Joachim H. Ficker

  2. Institut für Radiologie und Nuklearmedizin, Klinikum Nürnberg, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Germany

    Marco Galster

  3. Klinikum Nürnberg, Institut für Pathologie, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Germany

    Christian Meyer

Authors
  1. Markus Horneber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Galster
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joachim H. Ficker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Horneber, M., Galster, M., Meyer, C. et al. Checkpointinhibitor assoziierte Pneumonitiden. Im Fokus Onkologie 24, 30–34 (2021). https://doi.org/10.1007/s15015-021-3382-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-021-3382-x

Search

Navigation